CN100531757C - 一种治疗风热型感冒的药物组合物及其制备方法 - Google Patents
一种治疗风热型感冒的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN100531757C CN100531757C CNB2004101551012A CN200410155101A CN100531757C CN 100531757 C CN100531757 C CN 100531757C CN B2004101551012 A CNB2004101551012 A CN B2004101551012A CN 200410155101 A CN200410155101 A CN 200410155101A CN 100531757 C CN100531757 C CN 100531757C
- Authority
- CN
- China
- Prior art keywords
- water
- standby
- hour
- add
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 24
- 239000000203 mixture Substances 0.000 title claims description 7
- 239000003814 drug Substances 0.000 claims abstract description 143
- 239000007788 liquid Substances 0.000 claims abstract description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000013078 crystal Substances 0.000 claims abstract description 17
- 239000000341 volatile oil Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- 229940079593 drug Drugs 0.000 claims description 70
- 235000019441 ethanol Nutrition 0.000 claims description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 238000004821 distillation Methods 0.000 claims description 27
- 201000009240 nasopharyngitis Diseases 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims description 20
- 241000628997 Flos Species 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 238000004321 preservation Methods 0.000 claims description 14
- 239000010413 mother solution Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 238000007598 dipping method Methods 0.000 claims description 10
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims description 10
- 230000002879 macerating effect Effects 0.000 claims description 10
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 210000003298 dental enamel Anatomy 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000020374 simple syrup Nutrition 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 229940013618 stevioside Drugs 0.000 claims 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims 1
- 235000019202 steviosides Nutrition 0.000 claims 1
- 239000012153 distilled water Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract 2
- 235000015700 Artemisia abrotanum Nutrition 0.000 abstract 2
- 244000249062 Artemisia abrotanum Species 0.000 abstract 2
- 241000050051 Chelone glabra Species 0.000 abstract 2
- 244000111489 Gardenia augusta Species 0.000 abstract 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 2
- 235000011477 liquorice Nutrition 0.000 abstract 2
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000576429 Forsythia suspensa Species 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000011505 plaster Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 54
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 49
- 239000010931 gold Substances 0.000 description 49
- 229910052737 gold Inorganic materials 0.000 description 49
- 241001465754 Metazoa Species 0.000 description 32
- 230000000694 effects Effects 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 241000700605 Viruses Species 0.000 description 25
- 230000036760 body temperature Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 22
- 230000037396 body weight Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 206010037660 Pyrexia Diseases 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 230000036285 pathological change Effects 0.000 description 14
- 231100000915 pathological change Toxicity 0.000 description 14
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000011160 research Methods 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 229960001138 acetylsalicylic acid Drugs 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 241000194017 Streptococcus Species 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 230000002949 hemolytic effect Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 102000009338 Gastric Mucins Human genes 0.000 description 9
- 108010009066 Gastric Mucins Proteins 0.000 description 9
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 9
- 206010028748 Nasal obstruction Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 241000725643 Respiratory syncytial virus Species 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 239000009254 shuang-huang-lian Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 229940100050 virazole Drugs 0.000 description 6
- 208000031636 Body Temperature Changes Diseases 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 206010039101 Rhinorrhoea Diseases 0.000 description 5
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000002021 Enophthalmos Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000000887 face Anatomy 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000005723 virus inoculator Substances 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000011951 anti-virus test Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000004106 carminic acid Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000003067 hemagglutinative effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001679 citrus red 2 Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003861 dual diagnosis Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037377 skin turgor Effects 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
- 【权利要求1】一种治疗风热型感冒的药物组合物,其特征在于该药物组合物由以下重量配比的原料制成的:金银花13-18重量份、黄芩8-12重量份、柴胡8-12重量份、青蒿8-12重量份、连翘8-12重量份、虎杖8-12重量份、栀子8-12重量份、牡丹皮8-10重量份、羌活8-10重量份、甘草8-10重量份。
- 【权利要求2】根据权利要求1所述的治疗风热型感冒的药物组合物,其特征在于该药物组合由以下重量配比的原料制成的:金银花15重量份、黄芩10重量份、柴胡10重量份、青蒿10重量份、连翘10重量份、虎杖10重量份、栀子10重量份、牡丹皮9重量份、羌活8重量份、甘草8重量份。
- 【权利要求3】根据权利要求1或2所述的治疗风热型感冒的药物组合物,其特征在于由该药物组合物制成的制剂中还含有药物矫味剂或/和药物赋形剂。
- 【权利要求4】根据权利要求3所述的治疗风热型感冒的药物组合物,其特征在于所说的药物矫味剂为蔗糖、单糖浆、苯甲酸钠、甜菊甙、蛋白糖中的一种或一种以上的组合;所说的药物赋形剂为糊精、硬脂酸镁、微晶纤维素、羧甲基淀粉钠、淀粉、滑石粉、碳酸氢钠、枸椽酸中的一种或一种以上的组合。
- 【权利要求5】如权利要求1、2、3或4所述的治疗风热型感冒药物的液体制剂的制备方法,其特征在于该方法包括如下步骤:1、柴胡、羌活粉碎为3-4mm颗粒,与金银花、青蒿、连翘一起加水12-16倍,浸泡0.5-2小时,蒸馏4-7小时,收集芳香水,进行二次蒸馏,芳香水的收集量为药材量的0.8-1.5倍,加吐温-80使浓度为0.06%,备用,母液和水溶液分别另器备用;2、牡丹皮加水12-16倍,加4%-7%氯化钠,温浸1-3小时,蒸馏,收集7-10倍量蒸馏液,冷藏过夜,滤过,得结晶物,备用;蒸馏后的水溶液另器备用;3、上述药渣合并,加水8-12倍量,煎煮0.5-1小时,过滤,滤液与上述1、2项下蒸馏后的水溶液合并,备用;4、黄芩、虎杖、栀子、甘草粉碎为3-4mm颗粒,加水10-14倍,热浸1-2小时,煎煮2-4次,每次1-2小时,滤过,滤液与3项下药液合并,浓缩至90℃时相对密度为1.15—1.20的稠浸膏;5、待稠浸膏放冷至常温,加入乙醇,使含醇量达50%—65%,放置24-48小时,滤过,回收乙醇,在滤液中趁热加入以4-7倍量乙醇溶解的丹皮酚结晶物和芳香水,加入适量的药物矫味剂或/和药物赋形剂,制成口服液体制剂。
- 【权利要求6】如权利要求5所述的治疗风热型感冒药物的液体制剂的制备方法,其特征在于该方法包括如下步骤:1、柴胡、羌活粉碎为3~4mm颗粒,与金银花、青蒿、连翘一起加水15倍,浸泡1小时,蒸馏6小时,收集芳香水,进行二次蒸馏,芳香水的收集量为药材量的1倍,加吐温-80使浓度为0.06%,备用,母液和水溶液分别另器备用;2、牡丹皮加水15倍,加氯化钠5%,温浸2小时,蒸馏,收集9倍量蒸馏液,冷藏过夜,滤过,得结晶物,备用,蒸馏后的水溶液另器备用;3、上述药渣合并,加水10倍量,煎煮40分钟,过滤,滤液与上述1、2项下蒸馏后的水溶液合并,备用;4、黄芩、虎杖、栀子、甘草粉碎为3~4mm颗粒,加水12倍,热浸1小时,煎煮3次,每次1小时,滤过,滤液与3项下药液合并,浓缩至90℃时相对密度为1.18的稠浸膏;5、待稠浸膏放冷至常温,加入乙醇,使含醇量达60%,放置48小时,滤过,回收乙醇,滤液中趁热加入以5倍量乙醇溶解的丹皮酚结晶物和芳香水,冷藏24小时,滤过,加甜菊素及1项下母液,灌装成口服液。
- 【权利要求7】如权利要求1、2、3或4所述的一种治疗风热型感冒药物的固体制剂的制备方法,其特征在于该方法包括如下步骤:1、柴胡、羌活粉碎为3-4mm颗粒,与金银花、青蒿、连翘一起加水12-16倍,浸泡0.5-2小时,蒸馏4-7小时,收集挥发油,备用,母液及蒸馏后的水溶液另器备用;2、牡丹皮加水12-16倍,加4%-7%氯化钠,温浸1-3小时,蒸馏,收集7-10倍量蒸馏液,冷藏过夜,滤过,得结晶物,备用;蒸馏后的水溶液另器备用;3、取挥发油及丹皮酚结晶,加入3-6倍量的β-环糊精与8-12倍量的水研磨20-30min,将糊状物置入搪瓷盘中,40℃烘干,研碎过60目筛、备用;4、上述药渣合并,加水8-12倍量,煎煮0.5-1小时,过滤,滤液与上述1、2项下的水溶液合并,备用;5、黄芩、虎杖、栀子、甘草粉碎为3-4mm颗粒,加水10-14倍,热浸1-2小时,煎煮2-4次,每次1-2小时,滤过,滤液与4项下药液合并,在浓缩至60℃时相对密度为1.08~1.10的稠浸膏;6、待稠浸膏放冷至常温,加入乙醇,使含醇量达50—65%,放置24-48小时,滤过,回收乙醇,在浓缩至60℃时相对密度为1.08~1.10,干燥,再加入适量的药物矫味剂或/和药物赋形剂,制成口服固体制剂。
- 【权利要求8】如权利要求7所述的治疗风热型感冒药物的固体制剂的制备方法,其特征在于该方法包括如下步骤:1、柴胡、羌活粉碎为3-4mm颗粒,与金银花、青蒿、连翘一起加水15倍,浸泡1小时,蒸馏6小时,收集挥发油,备用,母液及蒸馏后的水溶液另器备用;2、牡丹皮加水15倍,加5%氯化钠,温浸2小时,蒸馏,收集9倍量蒸馏液,冷藏过夜,滤过,得结晶物,备用;蒸馏后的水溶液另器备用;3、取挥发油及丹皮酚结晶,加入4倍量的β-环糊精与10倍量的水研磨20min,将糊状物置入搪瓷盘中,40℃烘干,研碎过60目筛、备用;4、上述药渣合并,加水10倍量,煎煮40分钟,过滤,滤液与上述1、2项下的水溶液合并,备用;5、黄芩、虎杖、栀子、甘草粉碎为3-4mm颗粒,加水12倍,热浸1小时,煎煮3次,每次1小时,滤过,滤液与4项下药液合并,浓缩至60℃时相对密度为1.08~1.10的稠浸膏;6、待稠浸膏放冷至常温,加入乙醇,使含醇量达60%,放置48小时,滤过,回收乙醇,浓缩至60℃时相对密度为1.08~1.10,干燥,再加入适量的药物矫味剂或/和药物赋形剂,制成口服固体制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004101551012A CN100531757C (zh) | 2004-05-17 | 2004-05-17 | 一种治疗风热型感冒的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004101551012A CN100531757C (zh) | 2004-05-17 | 2004-05-17 | 一种治疗风热型感冒的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1579531A CN1579531A (zh) | 2005-02-16 |
CN100531757C true CN100531757C (zh) | 2009-08-26 |
Family
ID=34582244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004101551012A Expired - Lifetime CN100531757C (zh) | 2004-05-17 | 2004-05-17 | 一种治疗风热型感冒的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100531757C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100348258C (zh) * | 2005-11-01 | 2007-11-14 | 北京羚锐伟业科技有限公司 | 一种治疗上呼吸道感染的药物及其制备方法 |
CN102784282A (zh) * | 2012-08-27 | 2012-11-21 | 郑州同心堂生物科技有限公司 | 清热解毒退烧药物 |
CN103610766A (zh) * | 2013-11-28 | 2014-03-05 | 安徽联谊药业股份有限公司 | 一种散寒感冒胶囊 |
CN103989892A (zh) * | 2014-06-13 | 2014-08-20 | 李正梅 | 一种治疗感冒的小柴胡胶囊及其制备方法 |
CN104435822B (zh) * | 2014-11-15 | 2018-02-06 | 马梅青 | 一种清热解毒的中药制剂 |
CN104398965A (zh) * | 2014-12-01 | 2015-03-11 | 羊元庆 | 一种用于治疗病毒性感冒的中药 |
CN106728134A (zh) * | 2015-11-24 | 2017-05-31 | 哈尔滨墨医生物技术有限公司 | 一种青蒿清热含片及其生产方法 |
-
2004
- 2004-05-17 CN CNB2004101551012A patent/CN100531757C/zh not_active Expired - Lifetime
Non-Patent Citations (4)
Title |
---|
中医药治疗感冒发热摄要. 黄素嫦等.实用中医内科杂志,第16卷第3期. 2002 |
中医药治疗感冒发热摄要. 黄素嫦等.实用中医内科杂志,第16卷第3期. 2002 * |
掌握辩证用药规律灵活组方治感冒. 刘德泉.中国中医药报. 2004 |
掌握辩证用药规律灵活组方治感冒. 刘德泉.中国中医药报. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1579531A (zh) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102688332B (zh) | 一种治疗感冒的中药组合物及其制备方法 | |
CN100348258C (zh) | 一种治疗上呼吸道感染的药物及其制备方法 | |
CN101628108B (zh) | 治疗外感风寒的中药颗粒剂及其制备方法 | |
CN101322810B (zh) | 一种治疗上呼吸道感染的药物组合物 | |
CN102895326B (zh) | 一种治疗小儿感冒的中药组合物及其制备方法 | |
CN100531757C (zh) | 一种治疗风热型感冒的药物组合物及其制备方法 | |
CN103041030B (zh) | 一种治疗大头瘟的药物组合物及其制备方法和用途 | |
CN1903254B (zh) | 治疗风热感冒的复方药物及其制备方法 | |
CN101721614B (zh) | 一种具有清利咽喉和消肿止痛功效的药物组合物 | |
CN100502916C (zh) | 一种抗病毒的药物组合物及其制备方法 | |
CN101371905B (zh) | 一种治疗咽喉疾病的中药含片 | |
CN101411752A (zh) | 一种用于治疗小儿肺炎的颗粒剂 | |
CN103816281A (zh) | 一种预防和治疗风热感冒的中药组合物 | |
CN100435817C (zh) | 一种治疗呼吸系统疾患的中药组合物及其制备方法 | |
CN109432287B (zh) | 一种防治家禽气分热盛证的中药口服液及其制备方法 | |
CN104922530A (zh) | 一种防治鸡大肠杆菌病的药物组合物及其制备方法 | |
CN105343274A (zh) | 一种具有消炎止咳作用的药物组合物 | |
CN102078529B (zh) | 一种用于治疗小儿感冒的中药制剂 | |
CN106902175A (zh) | 一种治疗肛周湿疹的中药软膏剂 | |
CN101352489B (zh) | 一种治疗乳蛾的中药及其制备方法 | |
CN108144037B (zh) | 一种治疗咳嗽的中药组合物及其应用 | |
CN105709030A (zh) | 一种用于治疗外感高热的中药组合物及其制备方法 | |
CN104623349B (zh) | 治疗上呼吸道感染的药物组合物 | |
CN113813306A (zh) | 一种防治鸡传染性鼻炎的中药组合物 | |
CN113908208A (zh) | 一种保肝护肝的药物组合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YANGZHOU ZHONGHUI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHANG HONG Effective date: 20131108 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ju Xiaoping Inventor before: Zhang Hong |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG HONG TO: JU XIAOPING Free format text: CORRECT: ADDRESS; FROM: 100027 CHAOYANG, BEIJING TO: 225200 YANGZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131108 Address after: 225200 Jiangdu Jianghuai Road, Jiangsu District, Yangzhou, No. 188 Patentee after: YANGZHOU ZHONGHUI PHARMACEUTICAL Co.,Ltd. Address before: 100027, happy village, No. 55, Beijing, Chaoyang District Patentee before: Zhang Hong |
|
CX01 | Expiry of patent term |
Granted publication date: 20090826 |
|
CX01 | Expiry of patent term |